Sulphonylureas, magnesium and cardiac K+ ATP channels.
Matz
R
R
D000255:Adenosine Triphosphate / Q000502:physiology*; D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000401:mortality / Q000503:physiopathology*; D006321:Heart / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use; D008274:Magnesium / Q000502:physiology*; D015221:Potassium Channels / Q000187:drug effects / Q000502:physiology*; D013453:Sulfonylurea Compounds / Q000009:adverse effects / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D015221:Potassium Channels; D013453:Sulfonylurea Compounds; D000255:Adenosine Triphosphate; D008274:Magnesium